Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.43 |
| ▸ | FPR1 | P21462 | 2/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | SSTR1 | P30872 | 4/20 | 0.41 |
| ▸ | SSTR4 | P31391 | 4/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4925672 | 1.00 | GRM2 (0.43) | GRM2FPR1FPR2SSTR1SSTR4 | |
| SCHEMBL4925663 | 1.00 | GRM2 (0.43) | GRM2FPR1FPR2SSTR1SSTR4 | |
| SCHEMBL4886544 | 0.87 | SSTR1 (0.43) | SSTR1SSTR4HTR2CTACR1EPHX1 | |
| SCHEMBL4886553 | 0.87 | SSTR1 (0.43) | SSTR1SSTR4HTR2CTACR1EPHX1 | |
| SCHEMBL4886548 | 0.87 | SSTR1 (0.43) | SSTR1SSTR4HTR2CTACR1EPHX1 | |
| SCHEMBL4886233 | 0.86 | SSTR1 (0.42) | FPR1FPR2SSTR1SSTR4HTR2C | |
| SCHEMBL4886234 | 0.86 | SSTR1 (0.42) | FPR1FPR2SSTR1SSTR4HTR2C | |
| SCHEMBL4886238 | 0.86 | SSTR1 (0.42) | FPR1FPR2SSTR1SSTR4HTR2C | |
| SCHEMBL4893559 | 0.85 | TACR1 (0.47) | SSTR1SSTR4HTR2CTACR1 | |
| SCHEMBL4893547 | 0.85 | TACR1 (0.47) | SSTR1SSTR4HTR2CTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | PFIZER INC. | 2008-12-18 | — | — | US | disclosed |
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | EFREMOV IVAN | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | PAICS, TMBIM6, ABCG2 | GRM2 4477/4885FPR1 4687/4885FPR2 4619/4885 |
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | AZI2, PAICS, UGT2B7 | GRM2 4077/4885FPR1 4794/4885FPR2 4698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.